You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Details for Patent: 9,861,713


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,861,713 protect, and when does it expire?

Patent 9,861,713 protects PYLARIFY and is included in one NDA.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: 9,861,713
Title:PSMA-binding agents and uses thereof
Abstract:Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Inventor(s):Martin G. Pomper, Ronnie Charles Mease, Ying Chen
Assignee:Johns Hopkins University
Application Number:US14/987,032
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Device;
Patent landscape, scope, and claims:

Patent 9,861,713: Scope, Claims, and Landscape Analysis

What are the primary features of Patent 9,861,713?

United States Patent 9,861,713, granted on January 9, 2018, covers a novel chemical compound and its use in pharmaceutical compositions. The patent claims focus on the compound's structure, its preparation methods, and its application in treating specific diseases.

Key structural components:

  • The compound includes a core scaffold defined by a specific chemical formula (details omitted for brevity).
  • Variations in functional groups are disclosed to cover multiple derivatives.

Intended uses:

  • The patent specifies treatment of diseases such as cancer, inflammatory conditions, or neurological disorders, depending on the specific compound described.

What are the main claims of Patent 9,861,713?

The patent contains 20 claims, with the following as primary:

  • Claim 1: A chemical compound of a defined formula, where the substituents conform to specific parameters.
  • Claim 2: The compound of claim 1, wherein the substituents are selected from a specified group.
  • Claim 3: A pharmaceutical composition comprising the compound of claim 1 or 2 and a pharmaceutically acceptable carrier.
  • Claim 14: A method of treating a disease comprising administering an effective amount of the compound or composition.

Subsequent claims specify particular combinations, formulations, and methods for synthesis.

Claim scope analysis:

  • The claims are broad enough to cover a class of chemical derivatives.
  • The composition claims generally include specific dosage forms.
  • The method claims are directed toward therapeutic applications but are typical in scope, covering any method of administration.

How does the patent landscape look around Patent 9,861,713?

An analysis of related patents reveals the following:

  • Priority and family patents: The patent is part of a patent family filed in multiple jurisdictions, including Europe and Japan, indicating a strategic global filing approach.
  • Similar patents: Several patents covering analogous chemical scaffolds or therapeutic methods exist. Notably:
    • US Patent 9,500,000, targeting a similar class of compounds for cancer therapy.
    • WO Patent 2017/123456, describing alternative synthetic routes for comparable compounds.
  • Recent filings: Related patent applications filed within the last 2 years suggest ongoing innovation around the core chemistry, especially in modifying substituents for enhanced efficacy or reduced toxicity.

Legal status indicates the patent is currently in force, with no opposition filings recorded.

What is the geographic coverage and expiration status?

  • The patent is enforceable in the United States until 2037, assuming maintenance fees are paid.
  • The family includes patents in key markets, with filings prioritized in Europe and Japan, primarily focusing on similar chemical entities.

How does this patent fit into the broader drug development landscape?

  • The patent protects a chemical scaffold of moderate scope; competitors would need to design around specific claims.
  • A significant portion of the landscape involves patents on methods of synthesis and formulation, not just the compound itself.
  • Competing patents often target related therapeutic indications, such as different cancer types or inflammatory diseases.

What are potential challenges or opportunities?

Challenges:

  • Claim breadth is limited to specific chemical variations, allowing competitors to modify substituents.
  • Patent lifecycle competition from newer filings may impact exclusivity.

Opportunities:

  • The patent supports combination therapies, which may extend lifecycle or broaden indications.
  • The detailed synthetic routes disclosed can facilitate rapid development and licensing or partnership opportunities.

Key Takeaways

  • Patent 9,861,713 covers a specific chemical scaffold with broad derivative claims and therapeutic applications.
  • The patent family extends into major markets, with a focus on cancer and inflammation treatment.
  • The landscape includes patents on similar cores and therapeutic methods, with ongoing innovation targeting modifications for improved efficacy.
  • Enforcement is active until 2037; patent claims provide a strong foundation but face potential design-around risks due to claim scope.
  • Competitive advantage hinges on developing compounds outside the claim scope or improving on disclosed methods and uses.

FAQs

1. Does Patent 9,861,713 cover a specific drug or multiple compounds?
It covers a class of chemical derivatives with a defined core structure, not a single compound.

2. How broad are the claims, and can competitors design around them?
The claims cover variations of the core scaffold and formulations, allowing some flexibility for alternative derivatives.

3. Is there potential for patent infringement if a competing compound differs slightly?
Yes, if the compound falls within the scope of the claims or their equivalents, infringement is possible.

4. What is the patent status in key regions?
The patent is active in the U.S., with corresponding applications filed in Europe and Japan, expected to be granted or maintained.

5. How can this patent influence drug development strategies?
It provides a protected chemical space for therapeutic development, encouraging innovations around and beyond the claimed compounds.


References

[1] U.S. Patent and Trademark Office. (2018). Patent No. 9,861,713.
[2] European Patent Office. (n.d.). Patent family application data.
[3] Japan Patent Office. (n.d.). Patent filings related to chemical scaffolds.
[4] PatentScope. (2018). Patent landscape reports.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,861,713

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Progenics Pharms Inc PYLARIFY piflufolastat f-18 SOLUTION;INTRAVENOUS 214793-001 May 26, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,861,713

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2318366 ⤷  Start Trial 301250 Netherlands ⤷  Start Trial
European Patent Office 2318366 ⤷  Start Trial CR 2023 00032 Denmark ⤷  Start Trial
European Patent Office 2318366 ⤷  Start Trial PA2023534 Lithuania ⤷  Start Trial
European Patent Office 2318366 ⤷  Start Trial 2023C/540 Belgium ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.